Preoperative intravesical mitomycin C cuts NMIBC recurrence risk by 77% over five years
A recent study evaluated giving two doses of intravesical mitomycin C before transurethral resection of bladder tumor (TURBT) in patients with non‑muscle‑invasive bladder cancer (NMIBC).
Compared with TURBT alone, the pre‑operative mitomycin C regimen lowered the combined risk of tumor recurrence or death by 77% over a five‑year follow‑up.
These findings suggest that administering mitomycin C prior to surgery could become a valuable strategy to improve long‑term outcomes for NMIBC patients, pending further validation.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Preoperative Intravesical Mitomycin-C Before TURBT Cuts Recurrence Risk by 77% in NMIBC Over 5 Years”
read at onclive ↗
comments(0)
5-min edit window · permanent after that